See how AbbVie Inc. and Platinum Futures differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Platinum Futures represent standardized exchange-traded contracts linked to the future price of platinum. They are used by producers, consumers, traders, and investors to hedge exposure, express views on supply and demand, or gain commodity-market exposure. Their price is influenced by auto-catalyst demand, jewelry demand, industrial use, mine supply, investor flows, and the U.S. dollar.